17(R)‐Resolvin D1 differentially regulates TLR4‐mediated responses of primary human macrophages to purified LPS and live E. coli
暂无分享,去创建一个
[1] O. Levy,et al. Deficient expression of bactericidal/permeability-increasing protein in immunocompromised hosts: translational potential of replacement therapy. , 2011, Biochemical Society transactions.
[2] C. Serhan,et al. Saturated‐efferocytosis generates pro‐resolving CD11blow macrophages: Modulation by resolvins and glucocorticoids , 2011, European journal of immunology.
[3] C. Serhan,et al. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. , 2011, The Journal of clinical investigation.
[4] E. Porat,et al. Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia. , 2010, Journal of molecular and cellular cardiology.
[5] S. Gordon,et al. Alternative activation of macrophages: mechanism and functions. , 2010, Immunity.
[6] Petros P Sfikakis,et al. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. , 2010, Current directions in autoimmunity.
[7] M. Mizuno,et al. Lipoxin A4 Reduces Lipopolysaccharide-Induced Inflammation in Macrophages and Intestinal Epithelial Cells through Inhibition of Nuclear Factor-κB Activation , 2010, Journal of Pharmacology and Experimental Therapeutics.
[8] C. Serhan,et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors , 2010, Proceedings of the National Academy of Sciences.
[9] A. Cross. Development of an anti-endotoxin vaccine for sepsis. , 2010, Sub-cellular biochemistry.
[10] J. Takeda,et al. The Anti-Inflammatory and Proresolving Mediator Resolvin E1 Protects Mice from Bacterial Pneumonia and Acute Lung Injury , 2009, The Journal of Immunology.
[11] C. Andrés-Lacueva,et al. Ω-3 Polyunsaturated Fatty Acids and Immune-Mediated Diseases: Inflammatory Bowel Disease and Rheumatoid Arthritis , 2009 .
[12] H. Mobley,et al. Waging War against Uropathogenic Escherichia coli: Winning Back the Urinary Tract , 2009, Infection and Immunity.
[13] M. Ashcroft,et al. Diminished Macrophage Apoptosis and Reactive Oxygen Species Generation after Phorbol Ester Stimulation in Crohn's Disease , 2009, PloS one.
[14] C. Serhan,et al. Resolvin E1 Receptor Activation Signals Phosphorylation and Phagocytosis* , 2009, The Journal of Biological Chemistry.
[15] M. Perretti,et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis , 2009, Nature.
[16] C. Raetz,et al. Replacement of lipopolysaccharide with free lipid A molecules in Escherichia coli mutants lacking all core sugars. , 2009, Biochemistry.
[17] M. Wessels,et al. Inhibition of dendritic cell maturation by group A Streptococcus. , 2009, The Journal of infectious diseases.
[18] T. Sweeting,et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease , 2009, The Journal of experimental medicine.
[19] C. Serhan,et al. 15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. , 2009, American journal of respiratory and critical care medicine.
[20] S. Hernández-Díaz,et al. Endotoxin-Directed Innate Immunity in Tracheal Aspirates of Mechanically Ventilated Human Neonates , 2009, Pediatric Research.
[21] C. Sears,et al. Invasive fungal infections in the era of biologics. , 2009, Clinics in chest medicine.
[22] S. Akira,et al. ROLE OF TOLL-LIKE RECEPTORS 2 AND 4, AND THE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS IN HIGH-MOBILITY GROUP BOX 1-INDUCED INFLAMMATION IN VIVO , 2009, Shock.
[23] Masahira Hattori,et al. The Human Intestinal Microbiome: A New Frontier of Human Biology , 2009, DNA research : an international journal for rapid publication of reports on genes and genomes.
[24] K. Ley,et al. Neutrophil Adhesion and Activation under Flow , 2009, Microcirculation.
[25] C. Andrés-Lacueva,et al. Omega-3 polyunsaturated fatty acids and immune-mediated diseases: inflammatory bowel disease and rheumatoid arthritis. , 2009, Current pharmaceutical design.
[26] Sheng-hua Wu,et al. Elevated expressions of 15-lipoxygenase and lipoxin A4 in children with acute poststreptococcal glomerulonephritis. , 2009, The American journal of pathology.
[27] M. Abdollahi,et al. On the Use of Herbal Medicines in Management of Inflammatory Bowel Diseases: A Systematic Review of Animal and Human Studies , 2009, Digestive Diseases and Sciences.
[28] J. Edwards,et al. Exploring the full spectrum of macrophage activation , 2008, Nature Reviews Immunology.
[29] Sheng-hua Wu,et al. Signal pathway involved in inhibition by lipoxin A4 of production of interleukins induced in endothelial cells by lipopolysaccharide , 2008, Inflammation Research.
[30] D. Gilroy,et al. Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP , 2008, Blood.
[31] V. Gannon,et al. Escherichia coli O157:H7 Survives within Human Macrophages: Global Gene Expression Profile and Involvement of the Shiga Toxins , 2008, Infection and Immunity.
[32] Charles N. Serhan,et al. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators , 2008, Nature Reviews Immunology.
[33] N. Horwood,et al. Bmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NFkapp}B activity. , 2008, Blood.
[34] N. D. Dello Russo,et al. Human subjects. , 2008, Journal of the American Dental Association.
[35] Yan Lu,et al. Candida albicans Modulates Host Defense by Biosynthesizing the Pro-Resolving Mediator Resolvin E1 , 2007, PloS one.
[36] A. Cross,et al. Review: From therapy to experimental model: a hundred years of endotoxin administration to human subjects , 2007, Journal of endotoxin research.
[37] D. Ye,et al. Effects of lipoxin A4 on lipopolysaccharide induced proliferation and reactive oxygen species production in RAW264.7 macrophages through modulation of G-CSF secretion , 2007, Inflammation Research.
[38] Charles N. Serhan,et al. Resolvin E1 and protectin D1 activate inflammation-resolution programmes , 2007, Nature.
[39] D. Ye,et al. Lipoxin A4 negatively regulates lipopolysaccharide-induced differentiation of RAW264.7 murine macrophages into dendritic-like cells. , 2007, Chinese medical journal.
[40] J. Uddin,et al. Resolvin D1 and Its Aspirin-triggered 17R Epimer , 2007, Journal of Biological Chemistry.
[41] J. Duffield,et al. Resolvin D Series and Protectin D1 Mitigate Acute Kidney Injury1 , 2006, The Journal of Immunology.
[42] K. Tracey,et al. HMGB1 SIGNALS THROUGH TOLL-LIKE RECEPTOR (TLR) 4 AND TLR2 , 2006, Shock.
[43] C. Godson,et al. Lipoxin A4 Redistributes Myosin IIA and Cdc42 in Macrophages: Implications for Phagocytosis of Apoptotic Leukocytes1 , 2006, The Journal of Immunology.
[44] S. Opal,et al. Role of Toll-like receptors in infection and immunity: clinical implications. , 2006, Drugs.
[45] John Savill,et al. Resolution of inflammation: the beginning programs the end , 2005, Nature Immunology.
[46] J. Weiss,et al. Molecular Basis of Reduced Potency of Underacylated Endotoxins1 , 2005, The Journal of Immunology.
[47] Simon A. Jones,et al. Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-61 , 2005, The Journal of Immunology.
[48] F. Liew,et al. Negative regulation of Toll-like receptor-mediated immune responses , 2005, Nature Reviews Immunology.
[49] S. Opal,et al. Sepsis associated with immunosuppressive medications: An evidence-based review , 2004, Critical care medicine.
[50] S. Opal,et al. Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis. , 2004, Vaccine.
[51] S. Opal,et al. Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. , 2003, Vaccine.
[52] D. Wypij,et al. Endotoxemia and elevation of lipopolysaccharide-binding protein after hematopoietic stem cell transplantation , 2003, The Pediatric infectious disease journal.
[53] J. Steinke,et al. 2. Cytokines and chemokines. , 2003, The Journal of allergy and clinical immunology.
[54] Larry Borish,et al. Cytokines and chemokines , 2003 .
[55] S. Gordon. Alternative activation of macrophages , 2003, Nature Reviews Immunology.
[56] N. Petasis,et al. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. , 2002, Journal of the American Society of Nephrology : JASN.
[57] C. Serhan,et al. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-κB and AP-1 activation, and IL-8 gene expression in human leukocytes , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[58] J. Marshall,et al. Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence , 2002, Critical care.
[59] M. Feldmann,et al. Development of anti-TNF therapy for rheumatoid arthritis , 2002, Nature Reviews Immunology.
[60] S. Ramirez,et al. A Triple Mutant of Escherichia coli Lacking Secondary Acyl Chains on Lipid A* , 2002, The Journal of Biological Chemistry.
[61] O. Levy,et al. Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[62] K. Fukase,et al. Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition. , 2001, International immunology.
[63] Charles N. Serhan,et al. Lipid mediator class switching during acute inflammation: signals in resolution , 2001, Nature Immunology.
[64] G. Su,et al. Lipopolysaccharide-binding protein accelerates and augments Escherichia coli phagocytosis by alveolar macrophages. , 2000, The Journal of surgical research.
[65] Douglas T. Golenbock,et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus , 2000, Nature Immunology.
[66] S. Bustin. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. , 2000, Journal of molecular endocrinology.
[67] D. Morrison,et al. Differential Tumor Necrosis Factor Alpha Expression and Release from Peritoneal Mouse Macrophages In Vitro in Response to Proliferating Gram-Positive versus Gram-Negative Bacteria , 2000, Infection and Immunity.
[68] Hugh R. Brady,et al. Cutting Edge: Lipoxins Rapidly Stimulate Nonphlogistic Phagocytosis of Apoptotic Neutrophils by Monocyte-Derived Macrophages1 , 2000, The Journal of Immunology.
[69] Yoshinori Nagai,et al. MD-2, a Molecule that Confers Lipopolysaccharide Responsiveness on Toll-like Receptor 4 , 1999, The Journal of experimental medicine.
[70] S. Akira,et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. , 1999, Journal of immunology.
[71] W. Rocque,et al. Structural features and biochemical properties of TNF-α converting enzyme (TACE) , 1997, Journal of Neuroimmunology.
[72] R. Darveau,et al. A novel Escherichia coli lipid A mutant that produces an antiinflammatory lipopolysaccharide. , 1996, The Journal of clinical investigation.
[73] G. Strassmann,et al. Effect of liposome-mediated macrophage depletion on LPS-induced cytokine gene expression and radioprotection. , 1995, Journal of immunology.
[74] ビー. キャロル,シーン,et al. Prevention and treatment of sepsis , 1993 .
[75] Kevin J. Tracey,et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.
[76] D. Musher,et al. Phagocytosis and killing of common bacterial pathogens of the lung by human alveolar macrophages. , 1985, The Journal of infectious diseases.
[77] B. Andersen,et al. Electron Microscopical Study of Neisseria Meningitidis Releasing Various Amounts of Free Endotoxin , 1979, Acta pathologica et microbiologica Scandinavica. Section B, Microbiology.